A new way to edit genes in blood stem cells
Original title: CRISPR/Cas9 gene editing in hematopoietic stem and progenitor cells to accelerate the translation of cellular therapies and immunotherapies.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab cells and in mice.
The short version
Scientists found a better way to change blood stem cells in the lab.
What was studied. Researchers tested a gene editing tool called CRISPR/Cas9. They used it on blood stem cells from people and from mice.
What they found. The tool turned off target genes by up to 80%. The cells stayed alive. Edited mouse cells were able to rebuild bone marrow in mice. The team also turned off a gene called IL-6R. Those cells, given with immune drugs, helped treat glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary in mice.
What this means, and what it doesn't
What it could mean: This is a lab method, not a treatment. It may help scientists build and test cell therapies faster. Over time that could speed up brain tumor research.
What it doesn't mean: This does not mean a new brain tumor treatment is ready. The work was done in cells in a dish and in mice. It has not been tried in people. It is early science, far from everyday care. It is not a cure, and not a promise of one.
Source: PubMed, June 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.